太龙药业2025年半年报称，公司主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、 药品研发服务和药品药材流通四个业务板块。公司药品制剂业务以中药口服制剂为主，治疗领域覆盖呼 吸系统、心脑血管、消化系统、神经系统、生殖系统及妇科疾病。 太龙药业三季报显示，2025年前三季度，太龙药业实现营业收入11.87亿元，同比下降11.47%；实现归 母净利润2532.55万元，同比下降12.36%。 公司前三季度营业收入下降主要系公司主要产品参加全国中成药集采的执标工作尚未全面覆盖，"以价 换量"效果未能充分显现，叠加零售端药店整合等因素的影响。 太龙药业在最新披露的投资者关系记录表中表示，目前，公司药品制剂业务中选全国中成药集采的产品 执标工作正按各省份政策推进。四季度通常为呼吸道用药产品销售旺季，公司将结合市场需求统筹安排 合理库存，并综合考虑零售端药店整合调整及集采政策的影响，通过加强供应链及原材料成本管控，提 升运营效率，深化市场多渠道合作，保障产品供应需求，拓展市场份额。 （文章来源：中国证券报） 太龙药业12月1日晚间公告，控股股东郑州泰容产业投资有限公司（简称"泰容产投"）正在筹划公司股 份转 ...

中国经济网北京12月1日讯太龙药业（600222）(600222.SH)今晚发布关于控股股东筹划重大事项停牌的 公告。公司于2025年12月1日收到控股股东泰容产投的通知，泰容产投正在筹划股份转让事宜，该事项 可能导致公司控制权变更。 鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动， 根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第4号--停复牌》等有 关规定，经公司向上海证券交易所申请，公司股票(证券简称：太龙药业，证券代码：600222)自2025年 12月2日(星期二)开市起停牌，预计停牌时间不超过2个交易日。 ...

太龙药业控股股东筹划公司股份转让事宜，股票停牌 中国基金报记者 李智 12月1日晚间，太龙药业发布公告称，公司控股股东正在筹划公司股份转让事宜，可能导致公司控制权变更。经申请，公司股票自12月2日起停牌。 筹划公司控制权变更 太龙药业股票停牌 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | A 股 停牌 | 2025/12/2 | | | | 太龙药业表示，停牌期间，公司将根据事项进展情况，严格按照有关法律法规的规定和要求履行信息披露义务。上述筹划的重大事项尚存在不确定性，广 大投资者需关注后续公告，并注意投资风险。 前三季度业绩下滑 据悉，太龙药业的主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通四个业务板块。 12月1日，太龙药业发布公告称，公司控股股东郑州泰容产业投资有限公司（以下简称泰容产投）正在筹划公司股份转让事宜，可能导致公司控制权变 更。公司股票自12月2日起停牌，预计停牌时 ...

Core Viewpoint - Tai Long Pharmaceutical (600222) announced that its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd. ("Tai Rong Investment"), is planning a share transfer that may lead to a change in company control [2] Group 1: Shareholder and Control Changes - Tai Rong Investment holds 82.44 million shares, accounting for 14.37% of the total share capital, with a corresponding market value of approximately 707 million yuan [2] - The company will suspend trading from December 2, 2025, for no more than two trading days to avoid abnormal stock price fluctuations [2] - Tai Rong Investment acquired control of Tai Long Pharmaceutical in January 2022 at a price of 9.7 yuan per share, totaling around 800 million yuan [2] Group 2: Business Operations and Financial Performance - Tai Long Pharmaceutical focuses on drug manufacturing and research services, including four main business segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [3] - The company reported a net profit of 43.56 million yuan for 2023 and 50.53 million yuan for 2024, with a revenue of 1.187 billion yuan in the first three quarters of the current year, reflecting a year-on-year decline of 11.47% [3][4] - The decline in revenue is attributed to the ongoing standardization work for major products in the national collection of traditional Chinese medicine, which has not yet fully materialized [4] Group 3: Investor Returns - Tai Long Pharmaceutical plans to distribute cash dividends of 0.14 yuan per 10 shares to all shareholders before the third quarter of 2025, amounting to approximately 7.74 million yuan (including tax), which represents 30.57% of the company's net profit attributable to shareholders for the same period [4][5]

太龙药业（600222）明起停牌。 | 证券代码 | 证券简称 | 信分量则处 | | 停牌起始日 | 信 | 停牌终止日 | 复 雷日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期间 | | | | 600222 | 太龙药业 | A 股 | 信用 | 2025/12/2 | | | | 鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，根据有关规定，经公司向上海证券交 易所申请，公司股票（证券简称：太龙药业，证券代码：600222）自2025年12月2日（星期二）开市起停牌，预计停牌时间不超过2个交易 日。 12月1日晚间，太龙药业（600222）发布公告称，公司控股股东郑州泰容产业投资有限公司正在筹划公司股份转让事宜，该事项可能导致公 司控制权发生变更。 公开资料显示，太龙药业主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通四个业务板 块。 行情数据显示，今年以来，太龙药业股价表现较为强势，累计涨幅接近70%，尤其在近两个月加速上涨，11月 ...

Core Viewpoint - TaiLong Pharmaceutical (600222) announced a suspension of trading due to potential changes in company control as its major shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd., is planning to transfer shares [2][4]. Group 1: Company Announcement - The trading suspension for TaiLong Pharmaceutical will begin on December 2, 2025, and is expected to last no more than two trading days [4]. - The company operates in the pharmaceutical manufacturing and research services sector, which includes four main business segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [4]. Group 2: Stock Performance - TaiLong Pharmaceutical's stock has shown strong performance this year, with a cumulative increase of nearly 70%, and a significant rise of approximately 25% in November alone [4]. - On December 1, 2025, the stock reached a peak increase of 6.72%, bringing the total market capitalization to 4.9 billion [4]. Group 3: Financial Performance - For the first three quarters of the year, the company reported revenue of 1.187 billion, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million, down 12.36% [6]. - In the third quarter, the company achieved revenue of 424 million, a year-on-year increase of 2.67%, and a net profit of 5.98 million, reflecting a significant year-on-year growth of 162.48% [6]. - The adjusted net profit after excluding non-recurring items for the first three quarters was 20.73 million, showing a year-on-year increase of 6.38% [6].

太龙药业（600222）明起停牌。 12月1日晚间，太龙药业（600222）发布公告称，公司控股股东郑州泰容产业投资有限公司正在筹划公司股份转让事宜，该事项可能导致公司控制权 发生变更。 | 证券代码 | 证券简称 | 信分期 @ 地 | 停牌起始日 | 은 딸 | 停留级 上 | I | 夏牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | | 600222 | 太龙药业 | A B2 信 運 | 2025/12/2 | | | | | 鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，根据有关规定，经公司向上海证券交易所申 请，公司股票（证券简称：太龙药业，证券代码：600222）自2025年12月2日（星期二）开市起停牌，预计停牌时间不超过2个交易日。 公开资料显示，太龙药业主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通四个业务板块。 业绩方面，公司三季报显示，今年前三季度，公司实现营业收入11.87亿元，同比减少11.47 ...

Group 1: BYD Performance - BYD announced a production of 474,200 new energy vehicles (NEVs) and sales of 480,200 NEVs in November 2025 [1] - Cumulative production for the year reached 4,117,600 units, representing a year-on-year increase of 7.29% [1] - Cumulative sales for the year totaled 4,182,000 units, with a year-on-year growth of 11.30% [1] - In November, BYD exported 131,900 NEVs and installed approximately 27.669 GWh of power batteries and energy storage batteries [1] Group 2: Investment Initiatives - Lushin Venture Capital plans to establish a 400 million yuan investment fund focusing on life sciences, advanced manufacturing, and AI [2] - Chint Electric's wholly-owned subsidiary intends to invest up to 201 million yuan in a green private equity investment fund with a total scale of 700 million yuan [8] Group 3: Corporate Actions - Qianwei Central Kitchen will conduct a shareholder reward activity, offering a product package worth 200 yuan to individual shareholders holding 100 shares or more [3] - Huaxia Happiness plans to use trust beneficiary rights to offset financial debts totaling up to 24 billion yuan as part of its debt restructuring plan [4] - Tailong Pharmaceutical's controlling shareholder is planning a share transfer, leading to a temporary suspension of the company's stock [5] - ST Xianhe has applied to revoke other risk warnings, pending approval from the Shenzhen Stock Exchange [6] - *ST Yuancheng's stock will be delisted due to a market value below 500 million yuan for 20 consecutive trading days [7] Group 4: Sales and Contracts - SAIC Group reported sales of 4,108,000 vehicles from January to November 2025, a year-on-year increase of 16.4% [10] - Geely Automobile's total sales in November reached 310,428 units, marking a 24% increase year-on-year [11] - Far East Holdings' subsidiaries secured contracts worth 2.383 billion yuan in November, positively impacting future earnings [18] - Samsung Medical's subsidiary signed a contract for an annual bidding project in Indonesia worth approximately 160 million yuan [19] - Zhongchao Holdings' subsidiaries recently won contracts totaling 1.318 billion yuan [20] - Changhua Group received a project development notice from a domestic automaker, with an expected total sales amount of approximately 732 million yuan [21]

Group 1 - The core point of the news is that Tai Long Pharmaceutical's controlling shareholder is planning to transfer shares, which may lead to a change in company control, resulting in the suspension of the company's stock from December 2 [1][2][5] - The stock suspension is expected to last no more than two trading days, and the company will comply with legal disclosure obligations during this period [2][5] - As of the end of the third quarter, the controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., holds 82,441,168 shares, accounting for 14.37% of the total shares [6][7] Group 2 - For the first three quarters of the year, Tai Long Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [9][10] - The company's main business includes pharmaceutical manufacturing and research services, divided into four segments: pharmaceutical formulations, traditional Chinese medicine pieces, pharmaceutical research services, and pharmaceutical materials circulation [6]

【导读】太龙药业控股股东筹划公司股份转让事宜，股票停牌 中国基金报记者 李智 12月1日晚间， 太龙药业 发布公告称，公司控股股东正在筹划公司股份转让事宜，可能导致 公司控制权变更。经申请，公司股票自12月2日起停牌。 筹划公司控制权变更 太龙药业股票停牌 12月1日，太龙药业发布公告称，公司控股股东郑州泰容产业投资有限公司（以下简称泰容产 投）正在筹划公司股份转让事宜，可能导致公司控制权变更。公司股票自12月2日起停牌，预 计停牌时间不超过2个交易日。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | A 股 停牌 | 2025/12/2 | | | | 太龙药业表示，停牌期间，公司将根据事项进展情况，严格按照有关法律法规的规定和要求 履行信息披露义务。上述筹划的重大事项尚存在不确定性，广大投资者需关注后续公告，并 注意投资风险。 前三季度业绩下滑 据悉，太龙药业的主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药 ...